Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck

Abundance and signaling of the epidermal growth factor receptor (EGFR) and programmed cell death protein ligand 1 (PD-L1) in head and neck squamous cell carcinoma (HNSCC) are not only genetically determined but are also subject to the traits of the tumor microenvironment, which has hitherto not been...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 623964
Main Authors Zahnreich, Sebastian, Gebrekidan, Senayit, Multhoff, Gabriele, Vaupel, Peter, Schmidberger, Heinz, Mayer, Arnulf
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 26.02.2021
Subjects
Online AccessGet full text
ISSN2234-943X
2234-943X
DOI10.3389/fonc.2021.623964

Cover

More Information
Summary:Abundance and signaling of the epidermal growth factor receptor (EGFR) and programmed cell death protein ligand 1 (PD-L1) in head and neck squamous cell carcinoma (HNSCC) are not only genetically determined but are also subject to the traits of the tumor microenvironment, which has hitherto not been clarified completely. We investigated the impact of hypoxia on the EGFR system and on PD-L1 in six HPV negative HNSCC cell lines in vitro and in FaDu xenografts in vivo . Protein levels of EGFR, AKT, pAKT, ERK1/2, pERK1/2, CA IX, cleaved PARP (apoptosis), LC3B (autophagy), and PD-L1 were quantified by western blot after oxygen deprivation or CoCl 2 , staurosporine, and erlotinib treatment. In FaDu xenograft tumors the expression of EGFR, CA IX andCD34 staining were analyzed. Reduced oxygen supply strongly downregulated EGFR protein levels and signaling in FaDu cells in vitro and in vivo , and a transient downregulation of EGFR signaling was found in three other HNSCC cell lines. PD-L1 was affected by oxygen deprivation in only one HNSCC cell line showing increased protein amounts. The results of this study indicate a significant impact of the traits of the tumor microenvironment on crucial molecular targets of cancer therapies with high clinical relevance for therapy resistance and response in HNSCC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Jan Bussink, Radboud University Nijmegen, Netherlands; Javier Oliver, Consejo Superior de Investigaciones Científicas (CSIC), Spain
This article was submitted to Head and Neck Cancer, a section of the journal Frontiers in Oncology
Edited by: Johannes Kaanders, Radboud University Nijmegen Medical Centre, Netherlands
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.623964